1. Generics Bulletin

Zydus Looks To Major US Buyer For New North American Head

Red Oak’s Punit Patel Begins Tenure As President And CEO In North America

 
• By Dave Wallace

Zydus Lifesciences has named Punit Patel, former president of CVS and Cardinal’s generics buying group Red Oak Sourcing, as the company’s new president and CEO for North America.

Zydus lifesciences building, India
Zydus Lifesciences has announced new North American leadership • Source: Shutterstock

Zydus Lifesciences has looked to a major US buyer for leadership of its North American business, appointing Punit Patel – the former president of CVS and Cardinal’s generics buying group Red Oak Sourcing – as its president and CEO for North America.

Red Oak is one of the three major buying groups in US generics, accounting for around of a third of generic drug purchases along with ClarusOne/McKesson at just over a fifth and Walgreens Boots Alliance at almost two-fifths

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Generics Bulletin

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

Pfizer Discusses Tariffs Amid International Slump For Oncology Biosimilars Revenue

 
• By Adam Zamecnik

Reflecting conversations across the wider pharmaceutical industry, Pfizer’s earnings call for the first quarter of 2025 focused on the sector’s response to the potential imposition of tariffs by the Trump administration.

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.